MedPath

Alglucosidase alfa

Generic Name
Alglucosidase alfa
Brand Names
Lumizyme, Myozyme
Drug Type
Biotech
Chemical Formula
-
CAS Number
420784-05-0
Unique Ingredient Identifier
DTI67O9503
Background

Aglucosidase alfa consists of the human enzyme acid alpha-glucosidase (GAA) which is essential for the degradation of glygogen to glucose in lysosomes. It is encoded by the most predominant of nine observed haplotypes of this gene. Aglucosidase alfa is produced by recombinant DNA technology in a Chinese hamster ovary cell line. Alglucosidase alfa degrades glycogen by catalyzing the hydrolysis of a-1,4- and a-1,6- glycosidic linkages of lysosomal glycogen. Structurally, Alglucosidase alfa is a glycoprotein with a calculated mass of 98,008 daltons for the 883 residue mature polypeptide chain, and a total mass of approximately 109,000 daltons, including carbohydrates. It is used for the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients.

Indication

For the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients.

Associated Conditions
Glycogen Storage Disease Type II
Associated Therapies
-

Higher Dose of Alglucosidase Alpha for Pompe Disease

Not yet recruiting
Conditions
Glycogen Storage Disease Type II
First Posted Date
2021-08-23
Last Posted Date
2021-08-23
Lead Sponsor
Taipei Veterans General Hospital, Taiwan
Target Recruit Count
36
Registration Number
NCT05017402

Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatmen

Phase 4
Completed
Conditions
Pompe's Disease
Interventions
First Posted Date
2020-12-21
Last Posted Date
2024-08-13
Lead Sponsor
Genzyme, a Sanofi Company
Target Recruit Count
41
Registration Number
NCT04676373
Locations
🇨🇳

Investigational Site, China, China

A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease

Phase 4
Terminated
Conditions
Pompe Disease
Interventions
First Posted Date
2012-02-06
Last Posted Date
2015-12-08
Lead Sponsor
Genzyme, a Sanofi Company
Target Recruit Count
113
Registration Number
NCT01526785

A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II

Phase 2
Completed
Conditions
Glycogen Storage Disease Type II
Pompe Disease
Acid Maltase Deficiency Disease
Glycogenosis 2
Interventions
First Posted Date
2003-01-22
Last Posted Date
2014-02-05
Lead Sponsor
Genzyme, a Sanofi Company
Target Recruit Count
2
Registration Number
NCT00051935
Locations
🇺🇸

Saint Peter's University Hospital, New Brunswick, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath